News
352
Portfolio
10
Mentions
94
Employees: 11-50
Investment Stage: Series B; IPO
Portfolio 10
| Date | Name | Website | Total Raised | Location |
| 22.07.2026 | Crystalys ... | crystalystx.com | $130M | - |
| 08.07.2026 | Fore Bio | fore.bio | $180.4M | United Sta... |
| 07.05.2026 | CellCentri... | cellcentric.com | $391M | United Kin... |
| 08.01.2026 | Parabilis ... | parabilis.com | $305M | United Sta... |
| 15.12.2025 | Swixx BioP... | swixxbiopharma.com | $121.88M | Switzerlan... |
| 22.10.2025 | Electra Th... | electra-therapeutics.com | $267M | United Sta... |
| 28.03.2023 | ArriVent B... | arrivent.com | $415M | United Sta... |
| 17.10.2022 | Odyssey Th... | odysseytx.com | $487M | United Sta... |
| 18.06.2019 | Viela Bio ... | vielabio.com | $600M | United Sta... |
| 28.04.2017 | Amicus | amicuspharma.eu | $21.79M | Switzerlan... |
News 352
| Date | Title | Description |
| 24.07.2026 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments publishes Quarterly Report as at 30 June 2026 with key figures for the first three months of the 2026/2027 financial year | Widespread strong performance In the first quarter of the 2026/2027 financial year, HBM Healthcare Investments generated a profit of CHF 238 million. Once again, net assets exceeded the CHF 2 billion mark as at 30 June 2026. The net asset ... |
| 01.07.2026 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments delivers strong quarterly performance, expects profit of CHF 238 million | The portfolio of HBM Healthcare Investments delivered strong value growth in the past quarter. Net asset value per share (NAV), adjusted for the dividend payment, increased by 13.0% to CHF 306.20, while the share price rose by 8.9% to CHF 2... |
| 11.06.2026 | HBM Healthcare Investments benefits from successful IPO of Parabilis Medicines | HBM Healthcare Investments today announced the successful initial public offering of its portfolio company Parabilis Medicines (NASDAQ: PBLS), a clinical-stage biopharmaceutical company focused on developing novel cancer therapies. Parabili... |
| 01.06.2026 | HBM Healthcare Investments Announces Closing of Swixx Biopharma Transaction with SK Capital and Bain Capital Life Sciences | HBM Healthcare Investments today announced the successful closing of the previously disclosed transaction, in which funds advised by SK Capital Partners and Bain Capital Life Sciences acquired a majority equity interest in Swixx Biopharma f... |
| 26.05.2026 | Eli Lilly to Acquire HBM Portfolio Company Curevo for up to USD 1.5 Billion | HBM Healthcare Investments, an investment company specialising in the healthcare sector, announces that its privately held portfolio company Curevo Vaccine has entered into a definitive agreement to be acquired by Eli Lilly (NYSE: LLY). Und... |
| 13.05.2026 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments posts profit of CHF 272 million in its 25th financial year | HBM Healthcare Investments posts a profit of CHF 272 million in its 25th financial year ended 31 March 2026. The net asset value (NAV) per share in Swiss francs increased by 17.2 percent over the course of the year, while the share price r... |
| 01.04.2026 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments increases NAV by 17.2 percent and expects annual profit of CHF 272 million for the 2025/2026 financial year | HBM Healthcare Investments, an investment company specializing in the healthcare sector, successfully closed its 2025/2026 financial year as of 31 March. Over the course of the year, the net asset value (NAV) in Swiss francs increased by 17... |
| 25.03.2026 | Merck, Sharp & Dohme to Acquire HBM Portfolio Company Terns Pharmaceuticals for USD 6.7 Billion | HBM Healthcare Investments, a healthcare‑focused investment company, today announced that its publicly listed portfolio company, Terns Pharmaceuticals (Nasdaq: TERN), will be acquired by Merck Sharp & Dohme (“MSD”) (NYSE: MRK) for USD 5... |
| 23.01.2026 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments publishes Quarterly Report as at 31 December 2025 with key figures for the first nine months of the 2025/2026 financial year | Positive momentum following a considerably improved market environment HBM Healthcare Investments generated a profit of CHF 191 million in the third quarter of the 2025/2026 financial year. This brings the total profit for the first nine m... |
| 05.01.2026 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments once again delivered strong value growth in the 2025 calendar year despite currency headwind | HBM Healthcare Investments, an investment company specialising in the healthcare sector, looks back on a successful 2025 calendar year. The net asset value (NAV) increased by 14.8 percent in Swiss francs (31.4 percent in US Dollars) over th... |
| 15.12.2025 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments Announces Agreement to Sell Majority of Investment in Swixx Biopharma | HBM Healthcare Investments, an investment company focused on the healthcare sector, has announced the signing of a binding agreement to sell a majority stake in Swixx Biopharma. As part of the transaction, HBM Healthcare Investments, togeth... |
| 08.12.2025 | Mirum Pharmaceuticals to acquire HBM portfolio company Bluejay Therapeutics for up to USD 820 million | HBM Healthcare Investments, an investment company focused on the healthcare sector, announces that the shareholders of its privately held portfolio company Bluejay Therapeutics have approved a takeover by Mirum Pharmaceuticals (Nasdaq: MIRM... |
| 24.10.2025 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments publishes Half-Year Report as at 30 September 2025 with key figures for the first six months of the 2025/2026 financial year | Public portfolio companies’ strong performance easily offsets appreciation of the Swiss franc HBM Healthcare Investments posted a profit of CHF 96 million in the first half of the 2025/2026 financial year despite the strong appreciation of... |
| 01.10.2025 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments reports strong quarterly results – NAV rises by 16.4 per cent in the second quarter of the 2025/2026 financial year | HBM Healthcare Investments delivered a convincing performance in the second quarter of the 2025/2026 financial year, increasing its net asset value (NAV) per share by 16.4 per cent to CHF 251.78. This resulted in a quarterly profit of CHF 2... |
| 29.09.2025 | Genmab to Acquire HBM Portfolio Company Merus for USD 8 billion in Cash | HBM Healthcare Investments, a leading investor in global healthcare companies, announces that its listed portfolio company, Merus (Nasdaq: MRUS), has entered into a transaction agreement with Genmab (Nasdaq: GMAB). Genmab intends to acquire... |
| 10.09.2025 | HBM Portfolio Company Swixx BioPharma and Lundbeck Sign Multi-Regional CNS Partnership | HBM Healthcare Investments, a leading investor in global healthcare companies, announces that its portfolio company Swixx BioPharma, and its affiliated companies (Swixx) have signed a transformative, multi-regional distribution and services... |
| 18.07.2025 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments publishes Quarterly Report for the period ending 30 June 2025 | Quarterly result affected by unfavourable currency developments In the first three months of the 2025/2026 financial year, the value of the HBM Healthcare Investments portfolio increased by 0.5 percent in investment currencies. However, th... |
| 30.06.2025 | HBM Healthcare Investments AG completes share buyback programme | On 27 June 2025, HBM Healthcare Investments AG concluded its 2022 share buyback programme, which was initiated in June 2022. A total of 252,610 shares of HBM Healthcare Investments AG were repurchased via a separate trading line on the SIX ... |
| 15.05.2025 | Ad hoc announcement pursuant to Art. 53 LR2024/2025 financial year: HBM Healthcare achieved profit of CHF 19 million in a challenging environment | HBM Healthcare Investments generated an annual profit of CHF 19 million in the 2024/2025 financial year in a challenging environment. The net asset value per share (NAV) rose by 1.5 percent, while the share price declined slightly by –2.6 ... |
| 01.04.2025 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments expects to report a net profit of CHF 19 million for the 2024/2025 financial year | In a market environment that remains difficult for the biotech sector, HBM Healthcare Investments closed the 2024/2025 financial year with a net profit of CHF 19 million as of 31 March. Net asset value per share (NAV) rose by 1.5 percent to... |
| 20.03.2025 | Ad hoc announcement pursuant to Art. 53 LRSanofi to acquire DR-0201, a clinical-stage program of HBM portfolio company Dren Bio, for upfront amount of USD 600 million, plus potential milestones | HBM Healthcare Investments (SIX: HBMN) today announced that Dren Bio, a private portfolio company, and Sanofi have entered into a definitive agreement under which Sanofi has agreed to acquire DR-0201, a targeted bispecific myeloid cell enga... |
| 20.01.2025 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments publishes Quarterly Report as at 31 December 2024 with key figures for the first nine months of the 2024/2025 financial year | Positive result for the first nine months ended 31 December 2024 HBM Healthcare Investments generated a profit of CHF 66 million in the first nine months of the 2024/2025 financial year ended 31 December 2024. The performance in the first ... |
| 03.01.2025 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments reports a compelling 15 percent increase in NAV in the 2024 calendar year | HBM Healthcare Investments closed the calendar year 2024 with a strong performance. Its net asset value (NAV) per share rose by 15 percent to CHF 251.17. By contrast, the share price failed to reflect this good performance, growing only mar... |
| 18.12.2024 | Ad hoc announcement pursuant to Art. 53 LRSuccessful IPO of HBM portfolio company Sai Life Sciences on the Indian stock exchanges NSE and BSE increases NAV per HBM share by 3.2 percent | Sai Life Sciences (NSE/BSE: SAILIFE), a portfolio company of HBM Healthcare Investments, made a successful debut on the Indian stock exchanges NSE and BSE today. The company raised new capital of INR 9.5 billion (CHF 100 million) by issuing... |
| 21.10.2024 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments publishes Half-Year Report as at 30 September 2024 with key figures for the first six months of the 2024/2025 financial year | Successful first half – currency effects impact performance HBM Healthcare Investments generated a profit of CHF 23 million for the first six months of the 2024/2025 financial year ended 30 September 2024. Net asset value per share (NAV) r... |
| 14.10.2024 | HBM portfolio company Upstream Bio raises USD 255 million in successful initial public offering | Upstream Bio (Nasdaq: UPB), a previously private company in the HBM Healthcare Investments portfolio, got off to a successful start on the stock market last Friday. The company raised USD 255 million in new capital through the issuance of 1... |
| 01.10.2024 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments posts half-year profit of CHF 23 million for 2024/2025 financial year; currency effects had a strong negative impact on the result | HBM Healthcare Investments achieved a positive performance in the first half of the 2024/2025 financial year. The net asset value per share (NAV) increased by 1.5 per cent to CHF 244.34. The share price rose by 1.7 per cent to CHF 189.40. B... |
| 19.07.2024 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments publishes Quarterly Report as at 30 June 2024 with key figures for the first three months of the 2024/2025 financial year | Positive start to the new financial year HBM Healthcare Investments started the new 2024/2025 financial year with a quarterly profit of CHF 26 million. The net asset value per share (NAV) rose by 1.6 percent in the first three months to 30... |
| 28.05.2024 | Ad hoc announcement pursuant to Art. 53 LRHBM portfolio company Yellow Jersey Therapeutics to be acquired for USD 1.25 billion | HBM Healthcare Investments (SIX: HBMN) today announced that Yellow Jersey Therapeutics, a portfolio company, has entered into an agreement with Johson & Johnson, whereby Johnson & Johnson will acquire global rights to NM26, a Phase ... |
| 22.05.2024 | HBM Healthcare Investments' portfolio company Swixx BioPharma boosts sales and profits through strategic acquisition in Latin America | Swixx BioPharma, the largest investment in the private equity portfolio of HBM Healthcare Investments, today announced its strategic expansion into Latin America with the signing of an agreement to acquire the Laboratorios Biopas Group. The... |
| 08.05.2024 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments achieves a balanced result in the 2023/2024 financial year | HBM Healthcare Investments almost broke even in the 2023/2024 financial year with a slight loss of CHF 1 million. The net asset value per share (NAV) rose by 0.3 percent as the number of shares outstanding was reduced by share buy-backs. T... |
| 02.04.2024 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments publishes net asset value per share (NAV) of CHF 248.10 as at 31 March 2024 and quarterly profit of CHF 156 million | HBM Healthcare Investments generated a profit of CHF 156 million in the final quarter of the 2023/24 financial year as at the end of March. This largely made up for the loss from the first nine months. The net asset value per share (NAV) ro... |
| 22.01.2024 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments publishes Quarterly Report as at 31 December 2023 with key figures for the first nine months of the 2023/2024 financial year | Unfavourable currency developments drag HBM Healthcare into the red |
| 03.01.2024 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments publishes net asset value per share (NAV) of CHF 225.03 as at 31 December 2023 | HBM Healthcare Investments closed the 2023 calendar year with a negative performance due to unfavourable currency developments. The net asset value per share (NAV) fell by 8.3 percent to CHF 225.03. The share price declined by 5.4 percent t... |
| 30.11.2023 | AbbVie to acquire HBM portfolio company ImmunoGen for USD 10.1 billion in cash | HBM Healthcare Investments today announced that its portfolio company ImmunoGen (NASDAQ: IMGN) will be acquired by AbbVie (NYSE: ABBV) for USD 10.1 billion in cash. The acquisition price of USD 31.26 per ImmunoGen share represents a premium... |
| 16.10.2023 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments activates share buyback programme | The discount of the share price to the reported net asset value per share (NAV) has widened in recent days to an extent that the Board of Directors and the Management of HBM Healthcare Investments are convinced does not reflect the fundamen... |
| 16.10.2023 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments publishes Half-Year Report as at 30 September 2023 with key figures for the second quarter of the 2023/2024 financial year | |
| 02.10.2023 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments publishes Net Asset Value per Share (NAV) of CHF 237.22 as at 30 September 2023 | The net asset value per share (NAV) fell by 4.0 per cent to CHF 237.22 in the first six months of the 2023/2024 financial year. The performance thus is in line with the performance of the biotechnology sector as measured by the Nasdaq Biote... |
| 21.07.2023 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments publishes interim report for the quarter ended 30 June 2023 with key figures for the first three months of the 2023/2024 financial ... | Unfavourable currency developments push quarterly result into the red |
| 26.06.2023 | Ad hoc announcement pursuant to Art. 53 LRCathay Biotech raises capital and enters into major strategic collaboration with China Merchants Group | Cathay Biotech, the largest holding in HBM Healthcare Investments' portfolio (15% of net assets), yesterday announced a significant strategic collaboration with China Merchants Group (CMG). The transaction, which is subject to approval by C... |
| 26.05.2023 | Ad hoc announcement pursuant to Art. 53 LRPublication of Annual Report 2022/2023 and Invitation to the Ordinary Shareholders’ Meeting | The invitation to the 22nd Ordinary Shareholders’ Meeting on 19 June 2023 has been sent to the shareholders of HBM Healthcare Investments today. |
| 12.05.2023 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments year-end results 2022/2023 | HBM Healthcare Investments reports a loss of CHF 146 million for the 2022/2023 financial year. Inflation and rising interest rates led to declining valuations for technology and growth stocks around the globe. Four profitable acquisitions, ... |
| 03.04.2023 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments publishes net asset value per share of CHF 254.80 as at 31 March 2023 | HBM Healthcare Investments closed the fourth quarter of the 2022/2023 financial year ended on 31 March with a small increase in value. The net asset value per share (NAV) increased by 0.5 percent to CHF 254.80. The share price rose by 6.5 p... |
| 28.03.2023 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments announces the return of Dr Andreas Wicki; new investment of USD 12 million in ArriVent Biopharma | HBM Healthcare Investments refers to its media release dated 30 January 2023. Dr Andreas Wicki has recovered from his health matters and will fully resume his duties as Chief Executive Officer of HBM Healthcare Investments and with the inve... |
| 13.02.2023 | Successful IPO of HBM portfolio company Mineralys Therapeutics | Mineralys Therapeutics (Nasdaq: MLYS), a previously private company in the portfolio of HBM Healthcare Investments, successfully completed its IPO last Friday. The company placed 12 million new shares at a price of USD 16.00 per share, rais... |
| 30.01.2023 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments informs about a temporary change in the Executive Board | Dr Andreas Wicki, Chief Executive Officer of HBM Healthcare Investments, will be taking a brief leave of absence to adress a treatable health matter. Dr Wicki will remain involved to the extent practicable. |
| 20.01.2023 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments publishes Quarterly Report with key figures for the quarter ended 31 December 2022 and for the first nine months of the 2022/2023 f... | |
| 03.01.2023 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments publishes net asset value per share of CHF 253.59 as at 31 December 2022 | HBM Healthcare Investments suffered a negative performance for the calendar year 2022 in a declining market. The net asset value per share (NAV) declined by 21.7 percent to CHF 253.59. The share price fell by a much greater 37.8 percent to ... |
| 21.10.2022 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments Half-Year Report September 2022 | HBM Healthcare Investments recorded a decrease in value of CHF 86 million in the second quarter of the 2022/2023 financial year ended 30 September. The net asset value per share (NAV) declined by 4.2 percent. For the first half of the finan... |
| 03.10.2022 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments publishes Net Asset Value per Share (NAV) of CHF 270.92 as at 30 September 2022 | The net asset value per share (NAV) as at 30 September 2022 amounts to CHF 270.92 and is thus 1.7 percent lower than at the beginning of the current financial year 2022/23. In comparison, the MSCI World Health Care Sector Index declined by ... |
| 22.07.2022 | Ad hoc announcement pursuant to Art. 53 Listing RulesHBM Healthcare Investments Quarterly Report June 2022 | HBM Healthcare Investments achieved a net profit of CHF 52 million in the first quarter of the 2022/2023 financial year in an overall declining market environment. The net asset value per share rose by 2.6 percent, while the share price fel... |
| 28.06.2022 | HBM Healthcare Investments Ltd concludes 2019 share buyback programme and launches new share buyback programme | Yesterday, HBM Healthcare Investments Ltd concluded the 2019 share buyback programme that started in June 2019. Under the buyback programme, no registered shares were repurchased via the second trading line on the SIX Swiss Exchange. |
| 10.06.2022 | Shareholders’ Meeting of HBM Healthcare Investments approved all proposals by the Board of Directors | At today’s ordinary Shareholders’ Meeting of HBM Healthcare Investments Ltd the shareholders approved all proposals submitted by the Board of Directors. Based on the Federal Council's COVID 19 Ordinance 3, the meeting was held without the p... |
| 03.06.2022 | Bristol Myers Squibb to Acquire HBM Portfolio Company Turning Point Therapeutics for USD 4.1 billion in cash | HBM Healthcare Investments today announces that its portfolio company Turning Point Therapeutics (NASDAQ: TPTX) will be acquired by Bristol Myers Squibb (NYSE: BMY) in an all-cash transaction that values the company at USD 4.1 billion. The ... |
| 18.05.2022 | Ad hoc announcement pursuant to Art. 53 Listing RulesPublication of Annual Report 2021/2022 and Invitation to the Ordinary Shareholders’ Meeting | The invitation to the 21st Ordinary Shareholders’ Meeting on 10 June 2022 has been sent to the shareholders of HBM Healthcare Investments today. |
| 10.05.2022 | Pfizer to acquire HBM portfolio company Biohaven Pharmaceuticals in USD 11.6 billion deal | HBM Healthcare Investments today announces that its portfolio company Biohaven Pharmaceuticals (NYSE: BHVN) will be acquired by Pfizer (NYSE: PFE) for USD 11.6 billion in cash. The acquisition price of USD 148.50 per Biohaven share represen... |
| 06.05.2022 | Ad hoc announcement pursuant to Art. 53 Listing RulesHBM Healthcare Investments year-end results 2021/2022 | HBM Healthcare Investments reports a loss of CHF 78 million for the 2021/2022 financial year, for the first time in ten years and after a cumulative increase in value of 550 percent. The net asset value per share (NAV) fell by 3.6 percent a... |
| 01.04.2022 | Ad hoc announcement pursuant to Art. 53 Listing RulesHBM Healthcare Investments publishes Net Asset Value per Share (NAV) of CHF 285.53 as of 31 March 2022 | Following the previous year's record result, HBM Healthcare Investments experienced a slight decline in value in the 2021/22 financial year ended on 31 March 2022. The net asset value (NAV) per share fell by 3.6 percent to CHF 285.53. The s... |
| 21.01.2022 | Ad hoc announcement pursuant to Art. 53 Listing RulesHBM Healthcare Investments Quarterly Report December 2021 | HBM Healthcare Investments generated a net profit of CHF 4 million in the reporting quarter ended 31 December 2021. For the first nine months of the 2021/2022 financial year, the net profit amounts to CHF 275 million. Although the biotech s... |
| 03.01.2022 | Ad hoc announcement pursuant to Art. 53 Listing RulesHBM Healthcare Investments delivers strong return despite weak biotech sector and increases net asset value per share (NAV) by 19 percent in calend... | HBM Healthcare Investments closes the 2021 calendar year with another strong performance. The net asset value per share (NAV) rose by 19 percent to CHF 336.27 as at 31 December 2021, while the share price increased by 15.2 percent to close ... |
| 08.11.2021 | HBM Healthcare Investments benefits from the IPO of portfolio company IO Biotech | IO Biotech (Nasdaq: IOBT), a so far privately held company in the HBM Healthcare Investments portfolio, issued 7.15 million new shares at a price of USD 14.00 per share in last Friday's IPO on the US Nasdaq, raising USD 100 million in new c... |
| 22.10.2021 | Ad hoc announcement pursuant to Art. 53 Listing RulesHBM Healthcare Investments Half-year Report September 2021 | HBM Healthcare Investments generated for the first half of the financial year from 1 April to 30 September 2021, a profit of CHF 271 million while NAV increased by 12.6 percent to CHF 335.64. The share price rose 6.0 percent to CHF 340.00. |
| 01.10.2021 | Ad hoc announcement pursuant to Art. 53 Listing RulesHBM Healthcare Investments achieves value growth of 12.6 percent in the first half of the 2021/2022 financial year | HBM Healthcare Investments' net assets continued to grow in the first half of the 2021/2022 financial year, thanks to the excellent performance of the listed investment in Cathay Biotech in China and contributions from the private companies... |
| 23.07.2021 | Ad hoc announcement pursuant to Art. 53 Listing RulesHBM Healthcare Investments Quarterly Report June 2021 | HBM Healthcare Investments closed the first quarter of the 2021/2022 financial year with a profit of CHF 136 million. The increase in the net asset value per share (NAV) amounted to 6.3 percent. The share price rose by 6.9 percent. The inve... |
| 25.06.2021 | Ad hoc announcement pursuant to Art. 53 Listing RulesSuccessful IPO for HBM portfolio company Monte Rosa Therapeutics | Monte Rosa Therapeutics (Nasdaq: GLUE), a private company in the portfolio of HBM Healthcare Investments, reached an important milestone in the company's development with yesterday's successful IPO on Nasdaq. By issuing 11.7 million shares ... |
| 21.06.2021 | Ad hoc announcement pursuant to Art. 53 Listing RulesHBM portfolio company Ambrx Biopharma raises USD 126 million in initial public offering on New York Stock Exchange | Ambrx Biopharma (NYSE: AMAM), a private company in the portfolio of HBM Healthcare Investments, completed its initial public offering on the New York Stock Exchange last Friday. The company raised USD 126 million in new capital through the ... |
| 16.06.2021 | Ad hoc announcement pursuant to Art. 53 Listing RulesHBM Healthcare Investments has ended the subscription period for the bond early and increased the issue amount to CHF 100 million | HBM Healthcare Investments AG successfully completed the placement of the bond early, with Helvetische Bank AG and Raiffeisen Schweiz Cooperative acting as Joint-Lead Managers. Due to the strong demand, the coupon was fixed at the lower end... |
| 15.06.2021 | Ad hoc announcement pursuant to Art. 53 Listing RulesHBM Healthcare Investments Ltd announces the issue of a bond with a 6-year term and a minimum issue amount of CHF 60 million | HBM Healthcare Investments Ltd announces the issue of a bond with a 6-year term and a nominal amount of CHF 60 million with the possibility to increase the issue amount up to a maximum of CHF 75 million. The proceeds will be used to refinan... |
| 10.06.2021 | Ad hoc announcement pursuant to Art. 53 Listing RulesTata Digital to acquire majority stake in HBM portfolio company 1mg, India’s leading digital healthcare platform | HBM Healthcare Investments announced today, that Tata Digital, a fully-owned subsidiary of Tata Sons Private Limited, to acquire a majority stake of its privately held portfolio company 1mg. |
| 09.06.2021 | Ad hoc announcement pursuant to Art. 53 Listing RulesHBM portfolio company Valo Health and Khosla Ventures Acquisition Co. to combine and create publicly traded company | HBM Healthcare Investments announced today that its portfolio company Valo Health (“Valo”), a technology company using human-centric data and artificial intelligence (AI) powered computation to transform the drug discovery and development p... |
| 28.05.2021 | Ad hoc announcement pursuant to Art. 53 Listing RulesHBM portfolio company Swixx BioPharma announces EUR 45 million capital increase | Swixx BioPharma, a privately held company in the portfolio of HBM Healthcare Investments, today announced the signing of an investment agreement with Mérieux Equity Partners and its existing shareholders. Under the terms of the agreement, M... |
| 27.05.2021 | Invitation to the 20th Ordinary Shareholders' Meeting | Friday, 18 June 2021, 4.45 pm at the Company's registered office in Zug |
| 27.05.2021 | Ad hoc announcement pursuant to Art. 53 Listing RulesPublication of Annual Report 2020/2021 and Invitation to the Ordinary Shareholders’ Meeting | The invitation to the 20th Ordinary Shareholders’ Meeting on 18 June 2021 has been sent to the shareholders of HBM Healthcare Investments today. |
| 07.05.2021 | Ad hoc announcement pursuant to Art. 53 Listing RulesHBM Healthcare Investments reports a profit of CHF 756 million for the 2020/2021 financial year; Increase of the proposed cash distribution to a to... | In the 2020/2021 financial year, HBM Healthcare Investments recorded a profit of CHF 756 million, the highest since it was founded 20 years ago. The net asset value (NAV) rose by more than half (+52 percent) in the reporting year and the HB... |
| 07.05.2021 | Ad hoc announcement pursuant to Art. 53 Listing RulesChanges to the Board of Directors of HBM Healthcare Investments Ltd | Board of Directors of HBM Healthcare Investments Ltd proposes Dr Elaine V. Jones, an experienced and well connected executive, to be elected to the Board of Directors at the Shareholders' Meeting on 18 June 2021. In this regard, the Company... |
| 01.04.2021 | Ad hoc announcement pursuant to Art. 53 Listing RulesHBM Healthcare Investments closes anniversary year with record profit of over CHF 750 million | HBM Healthcare Investments will close its 20th financial year, ending on 31 March 2021, with a record result. The net asset value per share (NAV) rose by 52 percent to CHF 309.25. The share price climbed disproportionately by 79 percent to ... |
| 22.03.2021 | Ad hoc announcement pursuant to Art. 53 Listing RulesIPOs of Instil Bio and Connect Biopharma increase net asset value per HBM share by CHF 4.55 (+1.5%) | With Instil Bio (Nasdaq: TIL) and Connect Biopharma (Nasdaq: CNTB), two more private companies from the HBM Healthcare Investments portfolio successfully went public last Friday. |
| 15.03.2021 | Ad hoc announcement pursuant to Art. 53 Listing RulesSuccessful debut on the stock exchange for HBM portfolio company Longboard Pharmaceuticals | Longboard Pharmaceuticals (Nasdaq: LBPH), a private company in the portfolio of HBM Healthcare Investments, completed its IPO last Friday. The company raised USD 80 million in new capital by issuing 5 million shares at a price of USD 16.00 ... |
| 01.02.2021 | Ad hoc announcement pursuant to Art. 53 Listing RulesHorizon Therapeutics to acquire HBM portfolio company Viela Bio for USD 3.05 billion in cash | Horizon Therapeutics (Nasdaq: HZNP) and Viela Bio (Nasdaq: VIE) today announced that the companies have entered into a definitive agreement under which Horizon will acquire all of the issued and outstanding shares of Viela Bio for USD 53.00... |
| 22.01.2021 | Ad hoc announcement pursuant to Art. 53 Listing RulesHBM Healthcare Investments Quarterly Report December 2020 | HBM Healthcare Investments continued its impressive growth in net assets in the third quarter of the 2020/2021 financial year. Thanks to a quarterly profit of CHF 203 million with contributions from all portfolio categories, the result for ... |
| 04.01.2021 | Ad hoc announcement pursuant to Art. 53 Listing RulesHBM Healthcare Investments proves resilient: net asset value per share (NAV) up 36.7 percent in calendar year 2020, share price up 40.5 percent | HBM Healthcare Investments closed the volatile 2020 calendar year, marked by the uncertainties surrounding the Covid-19 pandemic, with an outstanding result. Net asset value per share (NAV) rose by a high 36.7 percent to CHF 293.21 as at 31... |
| 17.12.2020 | Ad hoc announcement pursuant to Art. 53 Listing RulesIPOs of Bioatla and Seer boost HBM Healthcare Investments’ net asset value per share | With Bioatla (Nasdaq: BCAB), another private company from the HBM Healthcare Investments portfolio successfully went public yesterday. The company placed 10.5 million new shares at USD 18.00, raising USD 189 million. On yesterday's first tr... |
| 02.11.2020 | HBM Healthcare Investments nominates Dr Elaine Jones for the election to the Board of Directors | The Board of Directors of HBM Healthcare Investments AG is nominating Dr Elaine Jones for the election to the Board of Directors at the Annual General Meeting on 18 June 2021. Dr Jones is an experienced biopharmaceutical executive with more... |
| 30.10.2020 | HBM-backed Galecto raises USD 85 million in Nasdaq IPO | Galecto (Nasdaq: GLTO), a privately held company in the portfolio of HBM Healthcare Investments, completed its intended IPO. The company placed 5.67 million new shares at a price of USD 15.00 per share, raising USD 85 million in new capital... |
| 28.10.2020 | HBM Healthcare Investments sells stake in Westmed Holding Company | HBM Healthcare Investments today announces that the shareholders of Westmed Holding Company («Westmed»), a privately held portfolio company based in Colorado, USA, have approved a merger of Westmed with a subsidiary of Sunmed Group Holdings... |
| 23.10.2020 | HBM Healthcare Investments Half-year Report September 2020 | HBM Healthcare Investments maintained its strong performance in the second quarter of the 2020/2021 financial year, with four IPOs and three takeovers making a substantial contribution to its quarterly profit of CHF 215 million. This took t... |
| 09.10.2020 | Successful IPO of Everest Medicines on the Hong Kong Stock Exchange | Everest Medicines (symbol: 1952 HK), a privately held company in the portfolio of HBM Healthcare Investments, today completed its announced initial public offering on the Hong Kong Stock Exchange. The company raised HKD 3.5 billion (CHF 413... |
| 05.10.2020 | HBM portfolio company C4 Therapeutics raises USD 182 million in initial public offering; marginal positive impact on NAV per HBM share | C4 Therapeutics (Nasdaq: CCCC), a private company in the portfolio of HBM Healthcare Investments, completed its planned IPO last Friday. The company raised USD 182 million in new capital by issuing 9.6 million shares at a price of USD 19.00... |
| 01.10.2020 | HBM Healthcare Investments expects net profit of around CHF 441 million for first half of financial year 2020/2021 | The net asset value per HBM share (NAV) increased by 30.5 percent to CHF 263.98 in the first six months of the financial year 2020/2021 ending on 31 March. The share price rose by 46.2 percent to CHF 270.00. The four IPO's of Cathay Biotech... |
| 14.09.2020 | Gilead Sciences to acquire HBM portfolio company Immunomedics | Gilead Sciences (Nasdaq: GILD) and Immunomedics (Nasdaq: IMMU), a listed portfolio company of HBM Healthcare Investments, announced yesterday that the companies have entered into a definitive agreement pursuant to which Gilead will acquire ... |
| 24.08.2020 | Bristol Myers Squibb acquires HBM portfolio company Forbius | Bristol Myers Squibb (NYSE: BMY) and Forbius, a privately held company in the portfolio of HBM Healthcare Investments, today announced that they have entered into a definitive agreement under which Bristol Myers Squibb will acquire Forbius.... |
| 20.08.2020 | Successful IPO for Harmony Biosciences; Net asset value per HBM share increases by CHF 14.74 (+5.5%) | The announced IPO of Harmony Biosciences Holdings (Nasdaq: HRMY), a so far privately held company in the portfolio of HBM Healthcare Investments, was successfully completed. The company placed 5.35 million new shares at a price of USD 24.00... |
| 12.08.2020 | HBM Healthcare Investments benefits strongly from the IPO of Cathay Biotech; Net asset value per HBM share increases by CHF 32.20 (+13.7%); Cathay stake grows to 24 percent of net assets | The initial public offering of Cathay Biotech (Chinese name: 上海凯赛生物技术股份有限公司) (SSE STAR Market: 688065), a so far privately held company in the portfolio of HBM Healthcare Investments, on the Chinese technology exchange in Shanghai ("SS... |
| 11.08.2020 | HBM portfolio company Harmony Biosciences announces details of its IPO | Harmony Biosciences Holdings, a private company in the portfolio of HBM Healthcare Investments, today announced the details of its planned IPO on the Nasdaq stock exchange. The company intends to issue 4.65 million new shares at a price of ... |
| 31.07.2020 | HBM Healthcare Investments informs about the IPO of Cathay Biotech; Positive impact on the net asset value per HBM share (NAV) expected | Cathay Biotech (Chinese name: 上海凯赛生物技术股份有限公司) (SSE STAR Market: 688065), a so far privately held company in the portfolio of HBM Healthcare Investments, today announced details of its initial public offering on the Chinese technology exchan... |
| 27.07.2020 | HBM portfolio company iTeos Therapeutics raises USD 201 million in initial public offering; marginal positive impact on NAV per HBM-share | iTeos Therapeutics (Nasdaq: ITOS), a private company in the portfolio of HBM Healthcare Investments, completed its planned IPO last Friday. The company raised USD 201 million in new capital by issuing 10.6 million shares at a price of USD 1... |
| 24.07.2020 | HBM Healthcare Investments Quarterly Report June 2020 | HBM Healthcare Investments looks back on a successful first quarter of the 2020/2021 financial year. The significant market recovery, positive corporate news and two acquisitions resulted in a net profit of CHF 226 million for the first thr... |
| 20.07.2020 | ALX Oncology's IPO positively impacts the net asset value per HBM share | ALX Oncology (Nasdaq: ALXO), a privately held company in the portfolio of HBM Healthcare Investments, successfully went public. The company placed 8.5million new shares at a price of USD 19.00 per share, raising a total of USD 161.5 million... |
| 01.07.2020 | Key Figures / Kennzahlen | |
| 11.06.2020 | Novo Nordisk acquires HBM portfolio company Corvidia Therapeutics for up to USD 2.1 billion in cash | Novo Nordisk (NYSE: NVO) today announced that it has entered into a definitive agreement to acquire Corvidia Therapeutics, a privately held company in the portfolio of HBM Healthcare Investments. |
Show more
Mentions in press and media 94
| Date | Title | Description |
| 30.08.2026 | Shape Memory Medical Raises $10 Million Led By August Global Partners To Advance Aortic Clinical Trials | Shape Memory Medical has closed a $10 million convertible note financing to advance clinical development of its shape memory polymer technology for aortic disease. New investor August Global Partners led the financing, with Taiwania Capital... |
| 24.07.2026 | Crystalys Therapeutics Announces $130 Million Series B Financing To Advance Gout Treatment Dotinurad | Crystalys Therapeutics announced the closing of an oversubscribed $130 million Series B financing to support late-stage global clinical development and commercialization preparation of dotinurad, a next-generation, once-daily, oral URAT1 in... |
| 22.07.2026 | Crystalys Therapeutics Raises $130 Million To Bring Late-Stage Gout Drug To U.S. Market | Crystalys Therapeutics raises $130 million in an oversubscribed Series B financing round. The funding will help Crystalys take its late-stage gout drug to market. Series B comes less than a year after its impressive $205 million Series A of... |
| 14.07.2026 | FORE Biotherapeutics Inks $67.4 Million Series D-2 Extension | PHILADELPHIA, PA, FORE Biotherapeutics, a company dedicated to developing targeted therapies to treat patients with cancer, announced the closing of an upsized Series D-2 extension financing of $67.4 million. >> Click here for more f... |
| 11.07.2026 | FORE Biotherapeutics Secures $110M Total Funding for Groundbreaking BRAF Cancer Drug | FORE Biotherapeutics secured $67.4 million, completing its Series D-2 funding at $110 million. This capital fuels plixorafenib, a next-generation BRAF inhibitor. The drug targets challenging BRAF-altered cancers, including primary CNS tumor... |
| 10.07.2026 | FORE Biotherapeutics Raises $67.4 Million In Series D-2 Extension To Advance Plixorafenib | FORE Biotherapeutics, a registration-stage oncology company focused on targeted cancer therapies, announced the closing of an upsized $67.4 million Series D-2 extension financing, bringing the total raised in the Series D-2 round to $110 mi... |
| 08.07.2026 | FORE Biotherapeutics Raises $67.4M to Advance BRAF Cancer Therapy | FORE Biotherapeutics Expands Funding for Late-Stage Cancer Program FORE Biotherapeutics has raised $67.4 million to support the development of its lead targeted cancer therapy, plixorafenib. The round was co-led by SR One, Medicxi, SymBiosi... |
| 08.07.2026 | FORE Biotherapeutics Raises $67.4M in Series D-2 Extension Funding | Fore Biotherapeutics, a Philadelphia, PA-based registration stage biotherapeutics company dedicated to developing targeted therapies to treat patients with cancer, raised $67.4M in Series D-2 extension funding. The round was led by SR One, ... |
| 29.06.2026 | Lycia Therapeutics Raises $75 Million Series D To Advance LYTAC Pipeline | Lycia Therapeutics announced that it has completed an oversubscribed $75 million Series D financing. The financing was co-led by existing investor Janus Henderson Investors and new investor Balyasny Asset Management. The round also included... |
| 29.06.2026 | Lycia Therapeutics Raises $75M in Series D Funding | Lycia Therapeutics, a South San Francisco, California-based developer of extracellular protein degradation and lysosomal targeting chimera (LYTAC) therapeutics, raised $75m in Series D funding. The round was co-led by Janus Henderson Invest... |
| 11.05.2026 | CellCentric Secures $220M to Accelerate Myeloma Drug Inobrodib | CellCentric secured $220 million in Series D funding. This capital fuels pivotal clinical trials for inobrodib. Inobrodib is a novel oral p300/CBP inhibitor. It targets relapsed or refractory multiple myeloma. Phase 2 data demonstrated sign... |
| 07.05.2026 | CellCentric: $220 Million Series D Raised To Advance Inobrodib Trials For Multiple Myeloma | CellCentric announced the completion of an oversubscribed $220 million Series D financing to support pivotal clinical trials of inobrodib, the company’s first-in-class oral p300/CBP inhibitor for the treatment of multiple myeloma. The finan... |
| 26.01.2026 | Corxel Raises Up to $287 Million In Series D1 To Advance Oral GLP 1 Program and Broader Cardiometabolic Pipeline | CORXEL Pharmaceuticals Limited said it has completed a Series D1 financing, raising up to $287 million to fund the development of CX11, its oral small molecule GLP-1 receptor agonist for obesity and overweight, as well as additional cardiom... |
| 26.01.2026 | Corxel Pharmaceuticals Raises $287M in Series D1 Funding | Corxel Pharmaceuticals, a Berkeley Heights, NJ-based clinical-stage biopharmaceutical company developing therapies for patients with cardiometabolic conditions, raised up to $287M in Series D1 funding. Backers included new investors includi... |
| 11.01.2026 | Parabilis Medicines Secures $305 Million for Cancer Drug Revolution | Parabilis Medicines recently closed an oversubscribed $305 million Series F financing round. This substantial capital propels its lead cancer candidate, zolucatetide, towards pivotal clinical trials for desmoid tumors and other challenging ... |
| 08.01.2026 | Parabilis Medicines: $305 Million Series F Raised To Advance Zolucatetide Program And Helicon Peptide Platform | Parabilis Medicines, a clinical-stage cancer drug developer, said it has closed an oversubscribed $305 million Series F financing to fund ongoing clinical development of its lead candidate FOG-001 (zolucatetide) across multiple tumor types ... |
| 08.01.2026 | Parabilis Medicines Raises $305M Series F Funding | Parabilis Medicines, a Cambridge, MA-based clinical-stage biopharmaceutical company committed to creating medicines for people living with cancer, closed a $305m Series F financing. The round was co-led by RA Capital Management, Fidelity Ma... |
| 17.12.2025 | SK Capital Invests Big in Biopharma Powerhouse Swixx | SK Capital Partners acquired a majority stake in Swixx Biopharma AG, valuing the biopharma commercialization leader over EUR 1.5 billion. This strategic investment boosts Swixx's global expansion and growth in underserved pharmaceutical mar... |
| 15.12.2025 | SK Capital acquires majority stake in Swixx Biopharma at EUR 1.5 billion valuation | HBM Healthcare Investments, an investment company focused on the healthcare sector, has announced the signing of a binding agreement to sell a majority stake in Swixx Biopharma. Swixx Biopharma has delivered exceptional growth, with revenu... |
| 15.12.2025 | SK Capital Announces Definitive Agreement to Invest in Swixx BioPharma AG to Drive the Next Phase of Growth and Global Expansion | SK Capital Partners, LP (“SK Capital”), a New York-based private investment firm focused on the life sciences, specialty materials, and ingredients sectors, today announced that its affiliate has reached an agreement to invest in Swixx BioP... |
| 23.10.2025 | Electra Therapeutics: $183 Million Series C Raised To Advance SIRP-Targeted Therapies For Immune Disorders And Cancer | Electra Therapeutics, a clinical-stage biotechnology company pioneering therapies against novel targets in immunology and cancer, has announced the close of an oversubscribed $183 million Series C financing round. The round was co-led by Ne... |
| 22.10.2025 | Electra Therapeutics Raises $183M in Series C Funding | Electra Therapeutics, a South San Francisco, CA-based clinical stage biotechnology company pioneering therapies against novel targets for diseases in immunology and cancer, raised $183m in Series C financing. The round was co-led by Nextech... |
| 22.10.2025 | EQT Life Sciences Co-Leads USD 183 Million Series C Financing in Electra Therapeutics | EQT Life Sciences Co-Leads USD 183 Million Series C Financing in Electra Therapeutics Wed, Oct 22, 2025 13:10 CET Report this content Electra Therapeutics is a late-stage biotechnology company developing new medicines for people with seriou... |
| 25.06.2025 | Neuron23: Pioneering Precision Medicine with a $96.5 Million Boost | In the ever-evolving landscape of biotechnology, Neuron23 stands as a beacon of hope. This San Francisco-based company has just secured $96.5 million in Series D funding, a significant leap forward in its mission to develop precision medici... |
| 25.06.2025 | Neuron23 Raises $96.5M in Series D Financing | Neuron23, a San Francisco, CA-based clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, raised $96.5M in Series D funding. The round wa sled by heal... |
| 24.06.2025 | Neuron23: $96.5 Million Series D Raised For Advancing Neurological And Immunological Medicines | Neuron23 – a clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases – announced the closing of a $96.5 million Series D funding round led by a healthcar... |
| 28.05.2025 | FORE Biotherapeutics: A New Dawn in Cancer Treatment with $38 Million Series D-2 Financing | In the ever-evolving landscape of cancer treatment, a new player is making waves. FORE Biotherapeutics, based in Philadelphia, has secured $38 million in Series D-2 financing. This funding marks a significant step forward in the company's m... |
| 23.05.2025 | FORE Biotherapeutics: $38 Million Series D-2 Raised For Advancement Of Plixorafenib | FORE Biotherapeutics, a registration-stage biotherapeutics company focused on developing targeted therapies to treat cancer patients, announced a $38 million Series D-2 financing. For this initial close of the Series D-2, leading healthcare... |
| 18.03.2025 | Curevo's $110 Million Bet on Shingles Vaccine: A Game Changer in Immunization | In the bustling world of biotechnology, Curevo Vaccine has made headlines with its recent $110 million Series B funding round. This infusion of capital is not just a financial boost; it’s a lifeline for a company on the brink of a significa... |
| 18.03.2025 | Curevo: $110 Million (Series B) Raised For Advancing Amezosvatein Shingles | Curevo Vaccine – a privately-held clinical-stage biotechnology company dedicated to developing varicella zoster virus (VZV) vaccines with improved tolerability – announced the closing of a $110 million Series B round to advance the developm... |
| 17.03.2025 | Curevo Raises $110M in Series B Funding | Curevo, a Seattle, WA-based clinical-stage biotechnology company, raised $110M in Series B funding. The round was led by Medicxi, with participation from OrbiMed, HBM Healthcare Investments, and Sanofi Ventures plus existing investors RA Ca... |
| 10.01.2025 | Numab Therapeutics: A Financial Surge in the Fight Against Cancer | In the world of biotechnology, where innovation meets investment, Numab Therapeutics has made headlines with its recent financial maneuvering. The Swiss company, known for its pioneering work in multi-specific antibodies, has successfully c... |
| 09.01.2025 | Numab raises additional CHF50 million | In 2024 Numab caused a stir with the acquisition of the biotech’s spin-out Yellow Jersey Therapeutics by Johnson & Johnson for $1.25 billion. Numab’s immuno-oncology therapeutic NM26 entered the clinic and the company started a collabo... |
| 21.11.2024 | Bain Capital-backed 360 ONE Asset bets on CDMO player from TPG’s portfolio | Tarun Sharma, head of healthcare and consumer, 360 One Asset 360 ONE Asset, an asset management firm backed by private equity firm Bain Capital, has invested in TPG-backed contract drugmaker OneSource Specialty Pharma in a secondary transac... |
| 16.10.2024 | Swiss investor HBM leads funding in TPG-backed drugmaker at $1.65 bn valuation | Premium Credit: 123RF.com Swiss investment firm HBM Healthcare has led a Rs 801 crore ($95 million) funding round in an Indian contract drug manufacturing company that also counts private equity firm TPG as an investor. HBM and other invest... |
| 03.05.2024 | Karius Revolutionizes Infectious Disease Diagnostics with $100M Funding Boost | Karius, a genomic diagnostics powerhouse, has secured a whopping $100 million in Series C funding to expand its groundbreaking Karius Test. This test, a game-changer in infectious disease diagnosis, uses cutting-edge genomic analysis and AI... |
| 02.05.2024 | Karius Raises $100M in Series C Funding | Karius, Inc., a Redwood City, CA-based leader in genomic diagnostics for infectious disease, raised $100m in Series C funding. The round was co-led by Khosla Ventures and new investors 5AM Ventures and Gilde Healthcare. Also investing was n... |
| 28.03.2023 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments announces the return of Dr Andreas Wicki; new investment of USD 12 million in ArriVent Biopharma | HBM Healthcare Investments refers to its media release dated 30 January 2023. Dr Andreas Wicki has recovered from his health matters and will fully resume his duties as Chief Executive Officer of HBM Healthcare Investments and with the inve... |
| 21.01.2022 | HBM Healthcare Investments Quarterly Report December 2021 | HBM Healthcare Investments AG / Key word(s): Quarter Results HBM Healthcare Investments Quarterly Report December 2021 21-Jan-2022 / 06:46 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible fo... |
| 21.01.2022 | HBM Healthcare Investments : Quarterly Report December 2021 | Quarterly Report 2021 December At a Glance Profile and Portfolio 2 HBM Healthcare Investments invests in the human medicine, biotechnology, medical techno logy and diagnostics sectors and related areas. The company holds and actively manag... |
| 03.01.2022 | HBM Healthcare Investments delivers strong return despite weak biotech sector and increases net asset value per share (NAV) by 19 percent in calendar year 2021 | EQS-Ad-hoc: HBM Healthcare Investments AG / Key word(s): Quarter Results HBM Healthcare Investments delivers strong return despite weak biotech sector and increases net asset value per share (NAV) by 19 percent in calendar year 2021 03-Jan-... |
| 08.11.2021 | HBM Healthcare Investments benefits from the IPO of portfolio company IO Biotech | EQS Group-News: HBM Healthcare Investments AG / Key word(s): IPO HBM Healthcare Investments benefits from the IPO of portfolio company IO Biotech 2021-11-08 / 06:46 ---------------------------------------------------------------------------... |
| 22.10.2021 | HBM Healthcare Investments : Half-year Report September 2021 | EQS Group-Ad-hoc: HBM Healthcare Investments AG / Key word(s): Half Year Results HBM Healthcare Investments Half-year Report September 2021 22-Oct-2021 / 06:45 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is ... |
| 22.10.2021 | HBM Healthcare Investments : Half-Year Report September 2021 | Half-Year Report2021 September At a Glance Profile and Portfolio 2 HBM Healthcare Investments invests in the human medicine, biotechnology, medical techno logy and diagnostics sectors and related areas. The company holds and actively manag... |
| 25.06.2021 | HBM Healthcare Investments : Successful IPO for HBM portfolio company Monte Rosa Therapeutics | EQS Group-Ad-hoc: HBM Healthcare Investments AG / Key word(s): IPO Successful IPO for HBM portfolio company Monte Rosa Therapeutics 25-Jun-2021 / 06:45 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely r... |
| 21.06.2021 | Ad hoc announcement pursuant to Art. 53 Listing RulesHBM portfolio company Ambrx Biopharma raises USD 126 million in initial public offering on New York Stock Exchange | Ambrx Biopharma (NYSE: AMAM), a private company in the portfolio of HBM Healthcare Investments, completed its initial public offering on the New York Stock Exchange last Friday. The company raised USD 126 million in new capital through the ... |
| 21.06.2021 | HBM HEALTHCARE INVESTMENTS AG HBM Healthcare Investments : portfolio company Ambrx Biopharma raises USD 126 million in initial public offering on New York Stock Exchange | EQS Group-Ad-hoc: HBM Healthcare Investments AG / Key word(s): IPO HBM portfolio company Ambrx Biopharma raises USD 126 million in initial public offering on New York Stock Exchange 21-Jun-2021 / 06:45 CET/CEST Release of an ad hoc announce... |
| 21.06.2021 | HBM Healthcare Investments : portfolio company Ambrx Biopharma raises USD 126 million in initial public offering on New York Stock Exchange | EQS Group-Ad-hoc: HBM Healthcare Investments AG / Key word(s): IPO HBM portfolio company Ambrx Biopharma raises USD 126 million in initial public offering on New York Stock Exchange 21-Jun-2021 / 06:45 CET/CEST Release of an ad hoc announce... |
| 15.06.2021 | HBM Healthcare Investments : announces the issue of a bond with a 6-year term and a minimum issue amount of CHF 60 million | EQS Group-Ad-hoc: HBM Healthcare Investments AG / Key word(s): Bond HBM Healthcare Investments Ltd announces the issue of a bond with a 6-year term and a minimum issue amount of CHF 60 million 15-Jun-2021 / 07:00 CET/CEST Release of an ad h... |
| 15.06.2021 | Ad hoc announcement pursuant to Art. 53 Listing RulesHBM Healthcare Investments Ltd announces the issue of a bond with a 6-year term and a minimum issue amount of CHF 60 million | HBM Healthcare Investments Ltd announces the issue of a bond with a 6-year term and a nominal amount of CHF 60 million with the possibility to increase the issue amount up to a maximum of CHF 75 million. The proceeds will be used to refinan... |
| 15.06.2021 | HBM HEALTHCARE INVESTMENTS AG HBM Healthcare Investments : announces the issue of a bond with a 6-year term and a minimum issue amount of CHF 60 million | EQS Group-Ad-hoc: HBM Healthcare Investments AG / Key word(s): Bond HBM Healthcare Investments Ltd announces the issue of a bond with a 6-year term and a minimum issue amount of CHF 60 million 15-Jun-2021 / 07:00 CET/CEST Release of an ad h... |
| 09.06.2021 | HBM Healthcare Investments : portfolio company Valo Health and Khosla Ventures Acquisition Co. to combine and create publicly traded company | EQS Group-Ad-hoc: HBM Healthcare Investments AG / Key word(s): Merger HBM portfolio company Valo Health and Khosla Ventures Acquisition Co. to combine and create publicly traded company 09-Jun-2021 / 18:51 CET/CEST Release of an ad hoc anno... |
| 28.05.2021 | HBM HEALTHCARE INVESTMENTS AG HBM Healthcare Investments : portfolio company Swixx BioPharma announces EUR 45 million capital increase | EQS Group-Ad-hoc: HBM Healthcare Investments AG / Key word(s): Capital Increase HBM portfolio company Swixx BioPharma announces EUR 45 million capital increase 28-May-2021 / 07:15 CET/CEST Release of an ad hoc announcement pursuant to Art. ... |
| 28.05.2021 | HBM Healthcare Investments : portfolio company Swixx BioPharma announces EUR 45 million capital increase | EQS Group-Ad-hoc: HBM Healthcare Investments AG / Key word(s): Capital Increase HBM portfolio company Swixx BioPharma announces EUR 45 million capital increase 28-May-2021 / 07:15 CET/CEST Release of an ad hoc announcement pursuant to Art. ... |
| 28.05.2021 | Ad hoc announcement pursuant to Art. 53 Listing RulesHBM portfolio company Swixx BioPharma announces EUR 45 million capital increase | Swixx BioPharma, a privately held company in the portfolio of HBM Healthcare Investments, today announced the signing of an investment agreement with Mérieux Equity Partners and its existing shareholders. Under the terms of the agreement, M... |
| 21.05.2021 | Swixx BioPharma secures close to €100 million to fuel its growth | The strong Swiss pharma and biotech cluster includes not only drug development companies but also service providers. Among them are fast growing companies such as Zug-based Swixx BioPharma which was founded under the name Amicus in 2013. Sw... |
| 21.05.2021 | Swixx BioPharma secures close to €100 million to fuel its growth | |
| 07.05.2021 | HBM HEALTHCARE INVESTMENTS AG HBM Healthcare Investments : reports a profit of CHF 756 million for the 2020/2021 financial year; Increase of the proposed cash distribution to a total of CHF 12.50 per... | EQS Group-Ad-hoc: HBM Healthcare Investments AG / Key word(s): Annual Results HBM Healthcare Investments reports a profit of CHF 756 million for the 2020/2021 financial year; Increase of the proposed cash distribution to a total of CHF 12.5... |
| 06.04.2021 | Mineralys Therapeutics Closes $40 Million Series A Funding | Aldosterone has been implicated as an underlying cause of hypertension in upwards of 30 percent of all hypertension patients and as such represents an ideal target for therapeutic intervention in these patients. In a Phase 1 study in health... |
| 01.04.2021 | Ad hoc announcement pursuant to Art. 53 Listing RulesHBM Healthcare Investments closes anniversary year with record profit of over CHF 750 million | HBM Healthcare Investments will close its 20th financial year, ending on 31 March 2021, with a record result. The net asset value per share (NAV) rose by 52 percent to CHF 309.25. The share price climbed disproportionately by 79 percent to ... |
| 22.03.2021 | HBM HEALTHCARE INVESTMENTS AG HBM Healthcare Investments : IPOs of Instil Bio and Connect Biopharma increase net asset value per HBM share by CHF 4.55 (+1.5%) | EQS Group-Ad-hoc: HBM Healthcare Investments AG / Key word(s): IPO IPOs of Instil Bio and Connect Biopharma increase net asset value per HBM share by CHF 4.55 (+1.5%) 22-March-2021 / 06:45 CET/CEST Release of an ad hoc announcement pursuant... |
| 22.03.2021 | HBM Healthcare Investments : IPOs of Instil Bio and Connect Biopharma increase net asset value per HBM share by CHF 4.55 (+1.5%) | EQS Group-Ad-hoc: HBM Healthcare Investments AG / Key word(s): IPO IPOs of Instil Bio and Connect Biopharma increase net asset value per HBM share by CHF 4.55 (+1.5%) 22-March-2021 / 06:45 CET/CEST Release of an ad hoc announcement pursuant... |
| 15.03.2021 | HBM Healthcare Investments : Successful debut on the stock exchange for HBM portfolio company Longboard Pharmaceuticals | EQS Group-Ad-hoc: HBM Healthcare Investments AG / Key word(s): IPO Successful debut on the stock exchange for HBM portfolio company Longboard Pharmaceuticals 15-March-2021 / 06:46 CET/CEST Release of an ad hoc announcement pursuant to Art. ... |
| 15.03.2021 | HBM HEALTHCARE INVESTMENTS AG HBM Healthcare Investments : Successful debut on the stock exchange for HBM portfolio company Longboard Pharmaceuticals | EQS Group-Ad-hoc: HBM Healthcare Investments AG / Key word(s): IPO Successful debut on the stock exchange for HBM portfolio company Longboard Pharmaceuticals 15-March-2021 / 06:46 CET/CEST Release of an ad hoc announcement pursuant to Art. ... |
| 22.01.2021 | HBM HEALTHCARE INVESTMENTS AG HBM Healthcare Investments : Quarterly Report December 2020 | EQS Group-Ad-hoc: HBM Healthcare Investments AG / Key word(s): Quarter Results HBM Healthcare Investments Quarterly Report December 2020 22-Jan-2021 / 06:45 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is sol... |
| 22.01.2021 | HBM Healthcare Investments : Quarterly Report December 2020 | EQS Group-Ad-hoc: HBM Healthcare Investments AG / Key word(s): Quarter Results HBM Healthcare Investments Quarterly Report December 2020 22-Jan-2021 / 06:45 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is sol... |
| 09.10.2020 | HBM HEALTHCARE INVESTMENTS AG HBM Healthcare Investments Media Release | Media Release Zug, 9 October 2020 Successful IPO of Everest Medicines on the Hong Kong Stock Exchange Everest Medicines (symbol: 1952 HK), a privately held company in the portfolio of HBM Healthcare Investments, today completed its announce... |
| 05.10.2020 | HBM portfolio company C4 Therapeutics raises USD 182 million in initial public offering; marginal positive impact on NAV per HBM share | C4 Therapeutics (Nasdaq: CCCC), a private company in the portfolio of HBM Healthcare Investments, completed its planned IPO last Friday. The company raised USD 182 million in new capital by issuing 9.6 million shares at a price of USD 19.00... |
| 05.10.2020 | HBM HEALTHCARE INVESTMENTS AG HBM Healthcare Investments Media Release | Media Release Zug, 5 October 2020 HBM portfolio company C4 Therapeutics raises USD 182 million in initial public offering; marginal positive impact on NAV per HBM share C4 Therapeutics (Nasdaq: CCCC), a private company in the portfolio of H... |
| 16.09.2020 | Polyneuron Extends Series A to CHF36.5 Million | Polyneuron will use the proceeds to advance its lead product candidate PN-1007, a potential treatment for anti-MAG neuropathy, a serious nervous system disease with a high unmet medical need, through Phase I/IIa clinical development. Clinic... |
| 16.09.2020 | Polyneuron Extends Series A to CHF36.5 Million | |
| 27.07.2020 | HBM portfolio company iTeos Therapeutics raises USD 201 million in initial public offering; marginal positive impact on NAV per HBM-share | iTeos Therapeutics (Nasdaq: ITOS), a private company in the portfolio of HBM Healthcare Investments, completed its planned IPO last Friday. The company raised USD 201 million in new capital by issuing 10.6 million shares at a price of USD 1... |
| 27.07.2020 | HBM HEALTHCARE INVESTMENTS AG HBM Healthcare Investments Media Release | Media Release Zug, 27 July 2020 HBM portfolio company iTeos Therapeutics raises USD 201 million in initial public offering; marginal positive impact on NAV per HBM-share iTeos Therapeutics (Nasdaq: ITOS), a private company in the portfolio ... |
| 17.06.2019 | HBM Healthcare Investments announces investment of USD 20 million in Viela Bio | Viela Bio, a privately held biotechnology company, today announced the successful completion of a USD 75 million private placement. HBM Healthcare Investments led the financing round and invested USD 20 million. Additional new investors inc... |
| 05.09.2018 | HBM Healthcare Investments takes USD 15 million stake in China's Leading Online Pharmacy and Healthcare Services Platform Jianke | Jianke, a privately held company based in Guangzhou, China, today announced the closing of a USD 130 million financing round. HBM Healthcare Investments participated with USD 15 million in this financing. |
| 29.03.2018 | Another successful IPO from HBM Healthcare Investments' portfolio: Homology Medicines raises USD 144 million | - |
| 20.10.2017 | BaseHealth Lands $8.5M for Predictive Analytics Platform to Uncover ‘Invisible Patients’ | BaseHealth, a predictive, evidence-based, and data-driven population health management solution that targets the unknown risk by identifying the “Invisible Patients” has raised $8.5 million in Series C funding led by HBM Healthcare Investme... |
| 18.10.2017 | BaseHealth raises $8.5M with an eye to pinpointing at-risk patients | Founded in 2011, BaseHealth takes an analytics-based approach to population health. Its predictive health platform gives organizations the information needed to identify patients at risk for 43 chronic diseases. Ultimately, the startup seek... |
| 06.10.2017 | HBM Healthcare Investments announces investment of USD 30 million in Harmony Biosciences | - |
| 28.04.2017 | HBM invests EUR 20 million in Amicus | |
| 31.05.2016 | India: 1mg raises funds from HBM Healthcare | Premium Online healthcare start-up 1mg Technologies Pvt. Ltd on Monday said it has raised undisclosed additional funding in its Series B round from global healthcare-focused fund HBM Healthcare Investments AG. Continue reading this story wi... |
| 18.05.2016 | HBM Healthcare Investments closes financial year 2015/2016 with earnings of CHF 23 million despite a negative market environment. Unchanged cash dividend of CHF 5.50 per share. | - |
| 01.04.2016 | HBM Healthcare Investments closes financial year 2015/2016 with earnings of CHF 23 million despite pronounced market correction in healthcare sector | - |
| 24.11.2015 | ObsEva Closes CHF 60 Million in Series B Financing | |
| 23.11.2015 | HBM Healthcare Investments participates in CHF 60 million financing of Swiss women’s health company ObsEva | - |
| 23.11.2015 | Daily funding roundup - November 23, 2015 | ColorChip raised $25M; Quizlet secured $12M; Sportpursuit received $14.4M funding South Korean apartment cleaning service WaHome has received $1 million in a seed investment from Sparklabs Global Ventures, Mashup Angels, Fast Track Asia and... |
| 30.06.2015 | HBM Healthcare Investments announces the issue of two bond tranches, one with a 6 year and the other with a 8 year term with a minimum issue amount of CHF 50 million each | - |
| 28.10.2014 | HBM Healthcare Investments takes USD 8 million stake in Vascular Dynamics | - |
| 17.02.2014 | HBM Healthcare Investments participates with EUR 20 million in financing round of Advanced Accelerator Applications | - |
| 06.11.2013 | Delenex Therapeutics closes CHF 7.3 Million Series A3 Financing | |
| 10.05.2013 | HBM Healthcare plans to invest in private companies again | |
| 23.07.2012 | Late-stage cystic fibrosis, muscular dystrophy drug raises $30 million | With cystic fibrosis the goal is to improve lung function and reduce pulmonary exacerbation. In a Phase 3 clinical study, Ataluren demonstrated trends in improvement in lung function when compared to a placebo. There were also trends in imp... |
| - | BaseHealth raises $8.5M with an eye to pinpointing at-risk patients | Sunnyvale, California-based BaseHealth has closed an $8.5 million Series C funding round, according to a news release. The round includes $2.5 million from lead investor HBM Healthcare Investments. Other investors weren’t disclosed in the r... |
| - | Late-stage cystic fibrosis, muscular dystrophy drug raises $30 million | A biopharmaceutical company with a cystic fibrosis drug in late-stage development has raised $30 million, according to a company statement. It was about $10 million less than the original funding target listed in a form D document with the ... |
Show more